@5_utr @KrishanJethwa Median survival with neoadjuvant CRT just 15.7 months. Also is resectable disease benefit not seen. We can do better https://t.co/UEARDtGNfX
So far, Altmetric has seen
216 X posts from 187 X users, with an upper bound of 1,576,235 followers.
1,274 followers
4,508 followers
@BijoyTelivala @SuyogCancer @agrothey @rachnatshroff @GIcancerDoc Don't forget about ESPAC-4...for patients who aren't able to tolerate adjuvant FOLFIRINOX, the other Level 1 evidence out there is for adjuvant gem-cape https://t.co/BCKnp3i0Qr
511 followers
ESPAC-4 Study: in patients with resectable pancreatic cancer, adjuvant gemcitabine + capecitabine increased Overall Survival compared to gemcitabine alone/ N=730 https://t.co/9mmmuUiI3J
4,646 followers